Adjuvant Cytotoxic Chemotherapy in Older Women (ACTION)
Disease site: Breast cancer
Treatment modality: Chemotherapy
ACTION was an NCRI phase III randomised controlled trial testing the benefit and tolerability of adjuvant chemotherapy in patients aged 70 and over with early stage ER negative or ER weakly positive breast cancer.
The aim of this trial was to address the following hypotheses:
- that adjuvant chemotherapy (either AC or EC) will increase the relapse free survival interval in older women with high risk breast cancer, and
- that two weekly (accelerated) therapy with GCSF support will not cause undue toxicity in this patient group, compared to the standard three weekly and that both chemotherapy regimens will be acceptable and tolerated in this group of patients
Chief Investigator: Professor Robert Leonard, Charing Cross Hospital, London
ICR-CTSU Scientific Lead: Professor Judith Bliss
Trial management contact: firstname.lastname@example.org
Sponsor: Institute of Cancer Research and Imperial College Healthcare NHS Trust
Funding: Cancer Research UK (CRUK/06/002), AMGEN
Publications and presentations
Leonard R, Ballinger R, Cameron D, et al. Adjuvant chemotherapy in older women (ACTION) study - what did we learn from the pilot phase? Br. J. Cancer 2011;105(9):1260-6.